Our clinical-stage monoclonal antibody, Xentuzumab – formerly known as BI 836845 – represents a significant effort by Astellas Inc. targeting PD-1. This journey initially focused on solid tumor treatments, but https://emilyohrb115303.aboutyoublog.com/54141202/xentuzumab-a-deep-investigation-into-bi-836845-and-its-progress